Suven Life Sciences secures four product patents for NCEs

09 Aug 2012 Evaluate

Suven Life Sciences (Suven) has secured the grant of four product patents, one each from Australia, Canada, Korea and New Zealand corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2026, 2027 and 2028.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, the company has a total of fifteen granted patents from Australia, nine from Canada, eight from Korea and thirteen granted patents from New Zealand. These granted patents are exclusive intellectual property of the company and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Sciences Share Price

150.15 -3.90 (-2.53%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×